You are here
Welcome / Review of Clinical Trial Experience and Perspective on Optimal Patient Selection for Regorafenib in mCRC
R.D. Hofheinz (Germany)
R.D. Hofheinz introduces the Symposium, exploring the evolution of the current treatment paradigm for mCRC and discussing appropriate patient selection for the integration of regorafenib into the treatment paradigm for pretreated mCRC.